Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 06, 2022

Second-Line Lisocabtagene Maraleucel vs Standard of Care With Salvage Chemotherapy Followed by Autologous HSCT Transplantation in Relapsed/Refractory LBCL

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Lancet 2022 Jun 18;399(10343)2294-2308, M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, S Ibrahimi, S Mielke, P Mutsaers, F Hernandez-Ilizaliturri, K Izutsu, F Morschhauser, M Lunning, DG Maloney, A Crotta, S Montheard, A Previtali, L Stepan, K Ogasawara, T Mack, JS Abramson,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading